Showing results (1-10 of 159) with videos related to
Sort By:
Pageof 16
The Canadian Journal of Cardiology|April 7, 2015
The new pooled cohort equations risk calculatorDavid Preiss, Søren L KristensenDiabetologia|April 27, 2016
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Naveed Sattar, James McLaren, Søren L Kristensen, et al.The Lancet. Diabetes & Endocrinology|August 19, 2019
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren L Kristensen, Rasmus Rørth, Pardeep S Jhund, et al.Diabetologia|December 28, 2016
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?David Preiss, Marion MafhamJournal of Clinical Monitoring and Computing|July 9, 2008
A measure of confidence in Bland-Altman analysis for the interchangeability of two methods of measurementDavid Preiss, Joseph FisherClinical Science (London, England : 1979)|July 30, 2008
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerationsDavid Preiss, Naveed SattarCurrent Opinion in Lipidology|September 8, 2011
Statins and the risk of new-onset diabetes: a review of recent evidenceDavid Preiss, Naveed SattarHeart (British Cardiac Society)|November 16, 2007
Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidenceDavid Preiss, Naveed SattarClinical Endocrinology|December 11, 2008
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidenceDavid Preiss, Naveed SattarDiabetic Medicine : a Journal of the British Diabetic Association|May 15, 2021
The effect of sodium-glucose transport protein 2 inhibitors on mortality and heart failure in randomized trials versus observational studiesJesper Krogh, Carsten Hjorthøj, Søren L Kristensen, et al.Pageof 16